title: Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis.
abstract: Some reports suggest that blood stem cell mobilization is difficult in a proportion of patients with CLL. We evaluated this issue in a large cohort of CLL patients. One hundred and twenty-eight patients with CLL underwent blood stem cell mobilization during 1995-2005 in Finland. Ninety-five percent of the patients had received fludarabine. The most common mobilization regimen was intermediate-dose CY plus G-CSF (90 patients, 70%). At least 2 x 10(6)/kg CD34+ cells were collected after the first mobilization attempt in 83 patients (65%), whereas 45 patients (35%) failed to reach this collection target. No differences were observed between these patient groups with regard to age, time from the diagnosis to mobilization, number of previous treatment lines, number of fludarabine courses, time from the last fludarabine-containing chemotherapy to mobilization, disease status or degree of marrow infiltration. Patients who failed collection had platelets <100 x 10(9)/l more commonly at the time of mobilization (30 vs 4%, P<0.001). A significant proportion of patients with CLL were difficult to mobilize. Adequate marrow function including platelet counts >100 x 10(9)/l seem to be important factors in terms of successful blood stem cell collection.
authors.affiliation: Department of Medicine, Kuopio University Hospital, Kuopio, Finland. esa.jantunen@kuh.fi
authors.forename: E
authors.initials: E
authors.lastname: Jantunen
authors.forename: M
authors.initials: M
authors.lastname: Itälä
authors.forename: T
authors.initials: T
authors.lastname: Siitonen
authors.forename: T
authors.initials: T
authors.lastname: Kuittinen
authors.forename: J
authors.initials: J
authors.lastname: Heiskanen
authors.forename: E
authors.initials: E
authors.lastname: Koivunen
authors.forename: E
authors.initials: E
authors.lastname: Juvonen
authors.forename: R
authors.initials: R
authors.lastname: Silvennoinen
authors.forename: T
authors.initials: T
authors.lastname: Nousiainen
authors.forename: P
authors.initials: P
authors.lastname: Koistinen
authors.forename: L
authors.initials: L
authors.lastname: Volin
authors.forename: K
authors.initials: K
authors.lastname: Remes
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005387:Finland; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D014182:Transplantation, Autologous; D017211:Treatment Failure; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D003115:Colony-Stimulating Factors; D019653:Myeloablative Agonists; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine